Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.

Diefenbach CS, Soslow RA, Iasonos A, Linkov I, Hedvat C, Bonham L, Singer J, Barakat RR, Aghajanian C, Dupont J.

Cancer. 2006 Oct 1;107(7):1511-9.

2.

Clinicopathologic analysis of early-stage sporadic ovarian carcinoma.

Leitao MM Jr, Boyd J, Hummer A, Olvera N, Arroyo CD, Venkatraman E, Baergen RN, Dizon DS, Barakat RR, Soslow RA.

Am J Surg Pathol. 2004 Feb;28(2):147-59.

PMID:
15043303
3.

Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis.

Niesporek S, Denkert C, Weichert W, Köbel M, Noske A, Sehouli J, Singer JW, Dietel M, Hauptmann S.

Br J Cancer. 2005 May 9;92(9):1729-36.

4.

Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.

Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR.

Am J Surg Pathol. 2005 Jun;29(6):707-23.

PMID:
15897738
5.

Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies.

Springett GM, Bonham L, Hummer A, Linkov I, Misra D, Ma C, Pezzoni G, Di Giovine S, Singer J, Kawasaki H, Spriggs D, Soslow R, Dupont J.

Cancer Res. 2005 Oct 15;65(20):9415-25. Erratum in: Cancer Res. 2005 Dec 15;65(24):11785.

6.

Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.

Chang SJ, Ryu HS, Chang KH, Yoo SC, Yoon JH.

Acta Obstet Gynecol Scand. 2008;87(4):476-81. doi: 10.1080/00016340801995640.

PMID:
18382877
7.

Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.

Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, O'Brien PM, Li Y.

Gynecol Oncol. 2009 Aug;114(2):265-72. doi: 10.1016/j.ygyno.2009.04.031.

PMID:
19450871
8.

Overexpression of mammaglobin B in epithelial ovarian carcinomas.

Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD.

Gynecol Oncol. 2007 Jun;105(3):578-85.

PMID:
17343903
9.

[Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].

Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.

Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Chinese.

PMID:
17631760
10.

Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.

Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, Diamandis EP.

Clin Cancer Res. 2001 Aug;7(8):2372-9.

11.

Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.

Bolat F, Gumurdulu D, Erkanli S, Kayaselcuk F, Zeren H, Ali Vardar M, Kuscu E.

Pathol Res Pract. 2008;204(6):379-87. doi: 10.1016/j.prp.2008.01.011.

PMID:
18343598
12.

Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.

Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, Wahlström T, Stenman UH.

Clin Cancer Res. 2004 Jul 15;10(14):4761-8.

13.

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC.

J Clin Oncol. 2008 Jul 10;26(20):3418-25. doi: 10.1200/JCO.2007.14.3420.

PMID:
18612157
14.

Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type.

Yamamoto S, Tsuda H, Honda K, Kita T, Takano M, Tamai S, Inazawa J, Yamada T, Matsubara O.

Mod Pathol. 2007 Dec;20(12):1278-85.

15.

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA.

Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009.

PMID:
19041126
16.

Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols.

Shan SJ, Scorilas A, Katsaros D, Rigault de la Longrais I, Massobrio M, Diamandis EP.

Clin Chem. 2006 Oct;52(10):1879-86.

17.

Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.

Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Gayther S, Jacobs IJ, Høgdall CK.

Gynecol Oncol. 2007 Aug;106(2):318-24.

PMID:
17540436
18.

Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.

Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y.

Gynecol Oncol. 2007 Jun;105(3):695-702.

PMID:
17368732
19.

Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.

Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S.

Cancer. 2006 Oct 15;107(8):1801-11.

20.

Relapse and survival in early-stage ovarian cancer.

Lenhard SM, Bufe A, Kümper C, Stieber P, Mayr D, Hertlein L, Kirschenhofer A, Friese K, Burges A.

Arch Gynecol Obstet. 2009 Jul;280(1):71-7. doi: 10.1007/s00404-008-0877-z.

PMID:
19093129
Items per page

Supplemental Content

Support Center